Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sivelestat sodium for postoperative spontaneous intracerebral hemorrhage
ChiCTR2600135525Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Harbin Medical University
- Start
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sivelestat in intracerebral hemorrhage (ICH) (2 arms), sponsored by The First Affiliated Hospital of Harbin Medical University. Primary endpoint: Poor functional outcome at 90 days after discharge. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
sivelestat
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on ChiCTR2600135525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135525.